Atea Pharmaceuticals announced it will hold a live conference call on May 12, 2026, to report its financial results for the first quarter ended March 31, 2026, and provide a business update. The company is a late-stage biopharmaceutical firm focused on developing oral antiviral therapies for serious viral diseases, including treatments for HCV and HEV. Investors can access the call via webcast or phone, with an archive available afterward. This update is important as Atea advances its antiviral drug pipeline, including Phase 3 trials and upcoming Phase 1 studies.
RENK Group AG, through its subsidiary RENK GmbH, has signed a binding agreement to acquire David Brown Defence, a UK company specializing in high-precision gearboxes for naval and land defense. This acquisition will strengthen RENK's naval sector por...
RENK Group AG, through its subsidiary RENK GmbH, has signed a binding agreement to acquire David Brown Defence, a UK-based company specializing in precision gearboxes for marine and land defense. This acquisition enhances RENK's marine sector portfol...
In June 2026, the cryptocurrency market experienced a significant correction driven by macroeconomic factors, with Bitcoin and Ethereum prices dropping over 20%. Institutional investors pulled approximately $4.5 billion from U.S. spot Bitcoin ETFs, m...
Bekaert continued its share buyback program from June 25 to July 1, 2026, repurchasing 50,043 shares at an average price of €39.50, totaling nearly €2 million. The company plans to cancel all repurchased shares, reducing outstanding shares and potent...
Sigenergy has introduced SigenStor Neo, a next-generation all-in-one residential energy storage system designed to provide complete energy independence. The system integrates five core components into one unit and supports dynamic electricity pricing...
